Loading

DUI

  • by Paul Armentano, NORML Deputy Director May 22, 2013

    A Michigan traffic safety law that prohibits the operation of a motor vehicle by persons who possess any presence of THC in their blood, regardless of whether or not they are behaviorally impaired by the substance, may not be strictly applied to state-qualified medical cannabis patients. So decided the Michigan Supreme Court on Tuesday in the case People v Koon.

    In a unanimous opinion, the Court determined that legal protections extended to state-qualified patients under the Michigan Medical Marihuana Act, enacted by voters in 2008, supersede the state’s zero tolerance, internal possession law. As a result, the Court determined that state prosecutors must establish that authorized patients charged under the statute are actually impaired by their cannabis use in order to gain a DUI criminal conviction.

    According to the syllabus of the Opinion:

    “The MMMA [Michigan Medical Marihuana Act] does not define what it means to be ‘under the influence,’ but the phrase clearly contemplates something more than having any amount of marijuana in one’s system and requires some effect on the person. Thus, the MMMA’s protections extend to a registered patient who internally possesses marijuana while operating a vehicle unless the patient is under the influence of marijuana. The immunity from prosecution provided under the MMMA to a registered patient who drives with indications of marijuana in his or her system but is not otherwise under the influence of marijuana inescapably conflicts with MCL 257.625(8) [the state's zero tolerance per se DUI law], which prohibits a person from driving with any amount of marijuana in her or system.”

    The state’s zero tolerance per se drug law remains applicable to non-patients. Under such laws, motorists are guilty per se (in fact) of a criminal traffic safety violation if they engage in the act of driving while detectable levels of certain controlled substances or, in some cases, their inert metabolites (byproducts) are present in the defendants’ blood or urine. Proof of actual impairment is not a requirement for a conviction under the law.

    To date, ten states — Arizona, Delaware, Georgia, Illinois, Indiana, Iowa, Michigan, Rhode Island, Utah, and Wisconsin — have enacted legislation imposing zero tolerance per se thresholds for the presence of cannabinoids and/or their metabolites. (State-authorized medical cannabis patients in Arizona and Rhode Island are exempt from prosecution under these per se statutes unless the state can provide additional evidence of psychomotor impairment.)

    Five additional states impose non-zero-tolerant per se thresholds for cannabinoids in blood: Montana (5ng/ml — law takes effect on October 1, 2013), Pennsylvania (1ng/ml), Ohio (2ng/ml), Nevada (2ng/ml) and Washington (5ng/ml). Most recently, Colorado lawmakers approved legislation stating that the presence of THC/blood levels above 5ng/ml “gives rise to permissible inference that the defendant was under the influence.” State-qualified patients in Colorado, Montana, and Nevada are not provided legal exemptions from these statutes, although legislation is presently pending in Nevada to do so.

    NORML believes that it is inadvisable to infer behavioral impairment based on the presence of blood/cannabinoid levels alone — a position that we outline here, here, and in public testimony here.

    Such caution is similarly expressed by the United States National Highway Transportation and Safety Administration, which acknowledges: “It is difficult to establish a relationship between a person’s THC blood or plasma concentration and performance impairing effects. … It is inadvisable to try and predict effects based on blood THC concentrations alone.”

    A 2013 review of per se drugged driving laws and their impact on road safety found “no evidence that per se drugged driving laws reduce traffic fatalities.”

  • by Paul Armentano, NORML Deputy Director January 14, 2013

    The imposition of so-called per se drugged driving laws, which create new traffic safety violations for drivers who operate a vehicle with the presence of trace amounts of certain controlled substances and/or their inert metabolites (byproducts) in their blood or urine, do not reduce incidences of traffic safety deaths.

    That’s the conclusion of a just-published study by economists at the University of Colorado, Denver and Montana State University. The study is available from the Institute for the Study of Labor (IZA) in Germany as a Discussion Paper.

    Since 1990, 11 states have passed so-called zero-tolerant per se drugged driving laws which make it illegal for one to drive with detectable levels of a controlled substance in his or her system. Five additional states have passed similar laws specifying non-zero limits for controlled substances or their metabolites. Fourteen (Arizona, Delaware, Georgia, Illinois, Indiana, Iowa, Michigan, Nevada, Ohio, Pennsylvania, Rhode Island, Utah, Washington, and Wisconsin) of these sixteen states impose these strict liability per se standards for cannabis. Recently, the White House Office of National Drug Control has recommended zero tolerant per se drug standards for all US states.

    Using state-level data from the Fatality Analysis Reporting System (FARS) for the period 1990-2010, authors examined the relationship between the adoption of controlled substance per se thresholds and overall incidences of traffic fatalities. They found that the relationship is statistically indistinguishable from zero and concluded that there is no evidence that these limits reduced traffic deaths.

    Authors reported: “Despite the fact that these laws have been touted by politicians and academics as an effective strategy for making our roadways safer, we find no evidence that they reduce traffic fatalities. … [W]e cannot determine why per se drugged driving laws do not work, and leave this issue to future researchers. However, our results clearly indicate that, as currently implemented, laws that make it illegal to drive with detectable levels of a controlled substance in the system have little to no effect on traffic fatalities.”

    In November, Washington state voters approved Initiative 502, which legalizes the private use and retail sale of cannabis to adults, but also imposes a 5ng/ml THC/blood per se limit for drivers over the age of 21. In Colorado, where voters on Election Day similarly legalized cannabis, Democrat Gov. John Hickenlooper and Republican Senator Steven King are calling for the passage of nearly identical per se cannabis legislation.

    NORML has consistently opposed the imposition of stand-alone per se limits for cannabinoids, arguing that the presence of THC in blood, particularly at lower levels, is an inconsistent predictor of behavioral impairment, particularly in more frequent consumers who may potentially test positive for trace, residual THC levels in their blood for periods of time exceeding any period of acute impairment.

    Operation of a motor vehicle while under the influence of cannabis is already a criminal offense in all 50 states. However, in order for one to gain a criminal conviction under most state DUI laws, prosecutors must prove that a motorist recently ingested cannabis and that doing so prohibited him or her from driving safely.

    Full text of the study, “Per Se Drugged Driving Laws and Traffic Fatalities,” is available online here. A separate paper previously published by the same authors reported that the passage of statewide medical marijuana laws is associated with decreased incidences of traffic fatalities.

  • by Erik Altieri, NORML Communications Director October 18, 2012

    At this year’s NORML Conference, which was held the first week of October, much emphasis was placed on the upcoming legalization initiatives in Washington, Colorado, and Oregon. One of the featured speakers was former NORML Board Member and writer for The Stranger in Washington, Dominic Holden. Dominic delivered an impassioned speech defending Washington’s marijuana legalization initiative, I-502, and spoke at length at the importance of winning initiatives and how we can progress towards full legalization in America.

    You can watch the video below:

    “The first [complaint of the opposition] is they don’t like a provision…that says if you have 5ng active THC in your blood for every mL of whole blood then you are guilty of DUI.

    What the opponents have been saying, is that someone who has used marijuana, a regular marijuana user…a medical marijuana user, will test positive for exceeding that level a day later, two days later, a week later. Well guess what? They don’t have a single f***ing scientific study to back them up. In fact, the science proves them wrong. What science shows is the vast majority of marijuana users drop below that 5ng level within a few hours and none within 12-24 hours and certainly not a day later, two days later, a week later. Their argument is fundamentally flawed, because it’s a lie.

    They are also concerned about a federal challenge, they say, “If we pass I-502 the federal government is going to challenge us on legalizing pot.”

    News Flash: That’s the damn point.”

    YouTube Preview Image

    Expect much more video coverage of this year’s NORML Conference in the coming days and be sure to visit www.newapproachwa.org to learn more about the effort to tax and regulate cannabis in Washington State this November.

  • by Erik Altieri, NORML Communications Director September 16, 2011

    This Week in WeedNow streaming on NORMLtv is the latest episode of “This Week in Weed.”

    This Week: a congressman calls upon Drug Czar Kerlikowse to reschedule marijuana, per se THC limits for drugged driving stall out in Colorado, and the biggest marijuana rally on the east coast is about to commence.

    Be sure to tune in to NORMLtv each Thursday afternoon to catch up on the latest marijuana news. Subscribe to NORMLtv or follow us on Twitter to be notified as soon as new content is added.

  • by Erik Altieri, NORML Communications Director March 25, 2011

    A new installment of ‘Ask NORML’ is now streaming on NORMLtv. This week’s topic, decided by our online audience, is drugged driving. In this episode, Executive Director Allen St. Pierre addresses concerns surrounding “stoned drivers” and the efficacy of current roadside testing.

    Subscribe to NORMLtv and visit NORML’s Facebook page for announcements regarding future ‘Ask NORML’ episodes. Please submit your medical use related questions here and we’ll do our best to answer as many as we can.

    Get active; get NORML!

    You can now follow NORMLtv on Twitter for up to the minute updates on new content and community engagement.

Page 1 of 212